Your dreams. Woven together.
ASAHI INTECC

Financial Results of Fiscal Year Ended June 2026

August 14, 2026

(Securities code: 7747　Prime of Tokyo Stock Exchange,
Premier of Nagoya Stock Exchange)

Contents

1. **Summary of Consolidated Financial Results of FYE June 2026**
2. Earnings Forecast for FYE June 2027

FYE June 2026 Main Points -1

Net sales **145,419 Mil.Yen** <Year-on-year **+21.2%**>

Increased in both Medical and Device Division driven by growing demand as well as the impact of exchange rates

- **Medical Division** **~Progressed favorably in both Cardiovascular and Non-cardiovascular~**
  - **Cardiovascular field: Increased mainly in PCI GW and Penetration catheter in all regions**
  - **Non-Cardiovascular field: Progressed favorably in Peripheral (all regions), Abdominal (all overseas regions) and Neurovascular (overseas regions)**
- **Device Division** **~ Increased in both Medical and Industrial Components ~**
  - **Increased both Medical and Industrial Components due to the consolidation of Nitta Mold as a subsidiary**
  - **Medical Components business: Increased in transactions of cardiovascular inspection catheter components for the U.S. and cardiovascular ultrasound catheter components for Asian markets**
  - **Industrial Components business: Increased in overseas leisure-related transactions**
- **Impact of exchange rate fluctuation (Yen depreciation) (+6,689 Mil. Yen)**

Exchange rate (Unit : JPY)	US $	EURO	CNY	BAHT
FYE June 2026 Full year	154.45	180.11	22.10	4.80
FYE June 2025 Full year	149.72	162.83	20.73	4.41

FYE June 2026 Main Points -2

Operating profit **45,218 Mil. Yen <YoY +50.3%>**

Operating profit increased significantly due to sales growth and a rise in the gross profit margin resulting from productivity improvement, etc.

- **Gross profit: 102,447 Mil.Yen ＜ YoY +26.1% ＞**
  - Increased due to sales growth and a rise in the gross profit margin (67.7% → 70.4%) driven by productivity improvement, etc.
  - Increased in cost of sales The impact of increased cost of sales due to U.S. tariffs YoY +1,149 Mil. Yen
- **Operating profit: 45,218 Mil.Yen ＜YoY +50.3% ＞**
  - The growth rate of SGA expenses has remained below the growth rate of net sales, while increased in sales-related expenses, R&D expenses and performance-linked bonuses (YoY +6,072 Mil. Yen, Sales ratio 39.4 %)
  - Increased in R&D expenses（13,372 Mil.Yen） （YoY +1,124 Mil.Yen, Sales ratio 9.2 %）
  - Decreased in goodwill amortization, etc. (YoY -1,137 Mil. Yen)
- **Ordinary profit: 45,185 Mil.Yen ＜YoY +52.8% ＞**
  - Non-operating income: Decreased in subsidy income （YoY –677 Mil.Yen)
  - Non-operating expenses: Decreased in foreign exchange losses （YoY –1,196 Mil.Yen)
- **Net income attributable to parent company shareholders: 32,075 Mil.Yen ＜YoY +151.8% ＞**
  - Extraordinary income: Increased gain on sale of investment securities (YoY +1,504 Mil.Yen)
  - Extraordinary loss: Decreased impairment losses (YoY -8,183 Mil. Yen), etc.

Highlights Year-on-Year

	FYE June 2025 Results		FYE June 2026 Results			
					YoY	
	Amount (Mil.Yen)	Ratio (%)	Amount (Mil.Yen)	Ratio (%)	Changes (Mil.Yen)	Changes (%)
Net sales	120,025	100.0	145,419	100.0	+25,394	+21.2
Gross Profit	81,235	67.7	102,447	70.4	+21,211	+26.1
Operating profit	30,079	25.1	45,218	31.1	+15,139	+50.3
Ordinary profit	29,563	24.6	45,185	31.1	+15,622	+52.8
Net income attributable to parent company shareholders	12,737	10.6	32,075	22.1	+19,337	+151.8
EPS (yen)	46.92	–	120.59	–	+73.67	+157.0

(Reference) At the same exchange rate as the previous year			
		YoY	
Amount (Mil.Yen)	Ratio (%)	Changes (Mil.Yen)	Changes (%)
138,730	100.0	+18,705	+15.6
97,272	70.1	+16,036	+19.7
41,329	29.8	+11,249	+37.4

Exchange rate (Unit : JPY)	US＄	EURO	CNY	BAHT
FYE June 2026 Full year	154.45	180.11	22.10	4.80
FYE June 2025 Full year	149.72	162.83	20.73	4.41

Highlights Compared to the Plan

	FYE June 2026 Revised Plan		FYE June 2026 Results			
					Compared to the Revised Plan	
	Amount (Mil.Yen)	Ratio (%)	Amount (Mil.Yen)	Ratio (%)	Changes (Mil.Yen)	Changes (%)
Net sales	**141,142**	**100.0**	**145,419**	**100.0**	**+4,277**	**+3.0**
Gross Profit	**98,658**	**69.9**	**102,447**	**70.4**	**+3,789**	**+3.8**
Operating Profit	**42,220**	**29.9**	**45,218**	**31.1**	**+2,998**	**+7.1**
Ordinary Income	**42,688**	**30.2**	**45,185**	**31.1**	**+2,497**	**+5.8**
Net income attributable to parent company shareholders	**30,556**	**21.6**	**32,075**	**22.1**	**+1,518**	**+5.0**
EPS (yen)	**114.88**	–	**120.59**	–	**+5.71**	**+5.0**

Exchange rate (Unit：JPY)	US＄	EURO	CNY	BAHT
FYE June 2026 Full year	**154.45**	**180.11**	**22.10**	**4.80**
FYE June 2026 Revised Plan	**152.87**	**177.40**	**21.33**	**4.79**

Sales/Operating profit by Segment Year-on-year

	FYE June 2025 Results		FYE June 2026 Results			
	Amount (Mil.Yen)	Ratio (%)	Amount (Mil.Yen)	Ratio (%)	Changes (Mil.Yen)	Changes (%)
Medical	107,779	89.8	126,798	87.2	+19,019	+17.6
Device	12,245	10.2	18,620	12.8	+6,374	+52.1
Total	120,025	100.0	145,419	100.0	+25,394	+21.2

(Reference)

Medical Field	115,799	96.5	138,658	95.4	+22,859	+19.7
Industrial Component Field	4,226	3.5	6,760	4.6	+2,534	+60.0

Operating profit						
Medical	33,445	31.0	46,190	36.4	+12,745	+38.1
Device	4,624	37.8	8,485	45.6	+3,861	+83.5
Erasing & Head Quarters	-7,990	–	-9,458	–	-1,467	+18.4
Total	30,079	25.1	45,218	31.1	+15,139	+50.3

(Reference)

Intersegment sales of Device Division	14,151	–	16,765	–	+2,614	+18.5

Earnings Performance by Segment





Per Segment by Medical Division (by Geography-1)



【Net sales (YoY)】 ~ Remained steady in all regions with positive effects from exchange rate ~

- Japan : Increased in Non-cardiovascular field
  - Cardiovascular field : Although PCI GW and Penetration catheter increased, products for inspection decreased(*), resulting in flat trend
  - Non-cardiovascular field : Strong sales of purchased products in Peripheral vascular (Penumbra) and Peripheral guidewires
- Overseas : Increased across all regions, with positive effects from exchange rate in all regions
  - US: Progressed well in brand products business
    - Cardiovascular field : Increased in PCI GW and Penetration catheter
    - Non-cardiovascular field : Increased in Abdominal and Peripheral vascular products
  - Europe: Progressed favorably due to increases in both direct sales and distributor transactions in Western Europe (YoY after considering forex impact +4.5%)
    - Cardiovascular field : Increased in PCI GW and Penetration catheter, while decreased in Guiding catheter*
    - Non-cardiovascular : Increased in Peripheral vascular and Abdominal vascular products
  - China: In addition to the high market growth rate, progressed favorably due to an expansion of market share and a decline in inflows from other regions (YoY after considering forex impact +24.1%)
    - Cardiovascular field : Progressed well mainly in PCI GW although balloon catheter decreased due to termination of transactions
    - Non-cardiovascular field : Increased in Abdominal and Peripheral vascular products
  - Other: Progressed well mainly in Asia
    - Cardiovascular field : Increased in PCI GW and Penetration catheters mainly in Asia
    - Non-cardiovascular field : Increased Peripheral, Abdominal vascular and Neurovascular products mainly in Asia

【Operating profit】 Operating profit increased in proportion to sales

(* Discontinuation of low-profit products)

ASAHI INTECC Your dreams. Woven together.

Per Segment by Medical Division (by Geography-2)

(Mil. Yen)			FYE June 2025 Results	FYE June 2026 Results	YoY	
					Changes	Changes (%)
Exchange rate (Yen)	USD		149.72	154.45	+4.73	+3.2
	EURO		162.83	180.11	+17.28	+10.6
	CNY		20.73	22.10	+1.37	+6.6
Total sales			107,779	126,798	+19,019	+17.6
	Japan		16,074	17,111	+1,037	+6.5
	Overseas		91,705	109,687	+17,981	+19.6
		US	23,043	26,186	+3,142	+13.6
		Europe	24,148	27,873	+3,724	+15.4
		China	28,283	37,417	+9,134	+32.3
		Other	16,229	18,209	+1,980	+12.2
Operating profit			33,445	46,190	+12,745	+38.1

Per Segment by Medical Division (by Treatment−1)



【Net sales (YoY)】

Cardiovascular

- Japan : Although PCI GW and Penetration catheter increased, products for inspection decreased(*), resulting flat trend
- Overseas : Increased across all regions, with positive effects from exchange rate
  - U.S.: Increased in PCI GW and Penetration catheter
  - Europe: Increased in PCI GW and Penetration catheter, and decreased in Guiding catheters(*)
  - China: PCI GW progressed well while balloon catheter decreased due to termination of transactions
  - Other: Increased in PCI GW and Penetration catheters mainly in Asia

(* Discontinuation of low-profit products)

Non-Cardiovascular

- Japan : Strong sales of purchased products in Peripheral vascular (Penumbra) and Peripheral guidewires
- Overseas : Increased in Peripheral vascular and Abdominal vascular across all overseas regions
  - U.S.: Increased in Abdominal and Peripheral vascular
  - Europe :Increased in Peripheral, Abdominal vascular
  - China : Increased in Abdominal vascular and Peripheral vascular
  - Other : Increased in Peripheral, Abdominal vascular and Neurovascular products mainly in Asia

OEM

- Japan : Decreased transactions due to business partner trends
- Overseas : Increased in contract development transactions in U.S.

Per Segment by Medical Division (by Treatment–2)

(Mil. Yen)		FYE June 2025 Results	FYE June 2026 Results	YoY	
				Changes	Changes(%)
Exchange rate (Yen)	USD	149.72	154.45	+4.73	+3.2
	EURO	162.83	180.11	+17.28	+10.6
	CNY	20.73	22.10	+1.37	+6.6
Total sales		107,779	126,798	+19,019	+17.6
	Japan	16,074	17,111	+1,037	+6.5
	Overseas	91,705	109,687	+17,981	+19.6
Cardiovascular		81,202	94,778	+13,576	+16.7
	Japan	8,629	8,675	+46	+0.5
	Overseas	72,572	86,103	+13,530	+18.6
Non-Cardiovascular		18,983	24,370	+5,386	+28.4
	Japan	5,799	6,850	+1,050	+18.1
	Overseas	13,184	17,520	+4,336	+32.9
OEM		7,593	7,650	+56	+0.7
	Japan	1,645	1,586	-59	-3.6
	Overseas	5,948	6,063	+115	+1.9

Per Segment by Device Division−1



【Net sales (YoY)】

~ Increased in both Medical components and Industrial components ~
Even excluding the consolidation of Nitta Mold as a subsidiary (+2,713 Mil. Yen) , results remained strong

Medical Component

- Japan : Increased due to the consolidation of Nitta Mold as a subsidiary
- Overseas : Increased transactions of cardiovascular inspection catheter components for the U.S. and transactions of cardiovascular ultrasound catheter components for Asian markets

Industrial Component

- Japan : Increased due to the consolidation of Nitta Mold as a subsidiary
- Overseas : Increased leisure-related transactions and due to the consolidation of Nitta Mold as a subsidiary

【Operating profit】

Increased due to growth in external sales and intersegment transaction

Per Segment by Device Division–2

(Mil. Yen)		FYE June 2025 Results	FYE June 2026 Results	(Increase due to the consolidation of Nitta Mold as a subsidiary) A	YoY		YoY excluding the impact of A	
					Changes	Changes (%)	Changes	Changes (%)
Exchange rate (Yen)	USD	149.72	154.45	-	+4.73	+3.2	-	-
Total sales		12,245	18,620	2,713	+6,374	+52.1	+3,660	+29.9
	Japan	2,805	3,732	1,119	+926	+33.0	-193	-6.9
	Overseas	9,439	14,888	1,594	+5,448	+57.7	+3,853	+40.8
Medical Components		8,019	11,859	762	+3,840	+47.9	+3,077	+38.4
	Japan	1,103	1,719	702	+615	+55.8	-86	-7.8
	Overseas	6,916	10,140	60	+3,224	+46.6	+3,164	+45.8
Industrial Components		4,226	6,760	1,951	+2,534	+60.0	+583	+13.8
	Japan	1,702	2,013	417	+310	+18.3	-106	-6.3
	Overseas	2,523	4,747	1,533	+2,223	+88.1	+689	+27.3
Operating profit		4,624	8,485	236	+3,861	+83.5	+3,625	+78.4
(Reference) Intersegment sales		14,151	16,765	-	+2,614	+18.5	-	-

Attribution Analysis of Operating profit – 1
(Exchange Rate Fluctuations Included)



Exchange rate (Unit：JPY)	US＄	EURO	CNY	BAHT
FYE June 2026 Full year	**154.45**	**180.11**	**22.10**	**4.80**
FYE June 2025 Full year	**149.72**	**162.83**	**20.73**	**4.41**

Your dreams. Woven together.
ASAHI INTECC

Attribution Analysis of Operating profit – 2
(Exchange Rate Fluctuations Excluded)



Exchange rate (Unit : JPY)	US $	EURO	CNY	BAHT
FYE June 2026 Full year	154.45	180.11	22.10	4.80
FYE June 2025 Full year	149.72	162.83	20.73	4.41

Reference: P/L

	FYE June 2025 Results		FYE June 2026 Results			
	Amount (Mil. Yen)	Ratio (%)	Amount (Mil. Yen)	Ratio (%)	Changes (Mil. Yen)	Main comparison factors
Net sales	120,025	100.0	145,419	100.0	+25,394	・Both Medical Division and Device Division performed well
Cost of sales	38,789	32.3	42,972	29.6	+4,182	
Gross profit	81,235	67.7	102,447	70.4	+21,211	・Increase in proportion to increasing sales and gross profit margin
SGA	51,155	42.6	57,228	39.4	+6,072	・Increase in expenses related to sales, R&D and performance-linked bonuses, etc.
Operating profit	30,079	25.1	45,218	31.1	+15,139	
Non-operating income	1,401	1.2	747	0.5	-654	・Decrease in subsidy income
Non-operating expense	1,918	1.6	780	0.5	-1,137	・Decrease in foreign exchange losses
Ordinary profit	29,563	24.6	45,185	31.1	+15,622	
Extraordinary income	123	0.1	1,527	1.1	+1,404	・Increase in gain on sale of investment securities
Extraordinary loss	11,031	9.2	2,018	1.4	-9,013	・Decrease in impairment losses, etc.
Net income attributable to parent company shareholders	12,737	10.6	32,075	22.1	+19,337	
Comprehensive income	9,375	7.8	40,065	27.6	+30,690	

Reference: B/S

		FYE June 2025 Results		FYE June 2026 Results			
		Amount (Mil. Yen)	Ratio (%)	Amount (Mil. Yen)	Ratio (%)	Changes (Mil. Yen)	Main comparison factors
Assets	Current assets	103,359	53.5	121,569	55.7	+18,209	**Cash and deposits** +10,063 **Inventories** +5,181 **Notes and accounts receivable-trade** +3,156
	Fixed assets	89,827	46.5	96,716	44.3	+6,888	**Tangible fixed assets** +4,004 **Investments and other assets** +3,361
Total assets		193,187	100.0	218,285	100.0	+25,098	
Liabilities	Current liabilities	27,856	14.4	32,124	14.7	+4,267	**Income taxes payable** +2,626 **Notes and accounts payable - trade** +1,996
	Fixed liabilities	13,976	7.2	11,803	5.4	-2,173	**Long-term borrowings** -2,357
Total liabilities		41,833	21.7	43,927	20.1	+2,094	
Total net assets		151,354	78.3	174,358	79.9	+23,004	**Retained earnings** +13,487 **Foreign currency translation adjustment** +7,285 **Treasury shares** +4,434 **Capital surplus** -2,907
Total liabilities & net assets		193,187	100.0	218,285	100.0	+25,098	

Reference: C/F



Contents

1. Summary of Consolidated Financial Results of FYE June 2026

2. **Earnings Forecast for FYE June 2027**

Outlook for FYE June 2027

Expected to increase in both Medical and Device divisions supported by expanding demands centered in overseas market

- **Net sales is expected to reach to 161,794 Mil. Yen (YoY +11.3%) due to growing overseas sales in Medical Division**
  - **Net sales YoY at the same exchange rate as the previous year +11.4%**
    (Net sales may decrease due to assumed exchange rate trends -175 million yen)
  - Medical Division: Cardiovascular/Growth is expected across all overseas market
    Non-cardiovascular/ Growth is expected across all regions and fields driven by market penetration
  - Device Division: Growth is expected in both Medical and Industrial components mainly through overseas business partner trends
- Operating profit is expected to reach to **52,127 Mil. Yen (YoY +15.3%)** supported by sales growth and productivity improvement
  - **Operating profit YoY at the same exchange rate as the previous year +16.7%**
  - **Gross profit 114,737 Mil. Yen (YoY +12.0%)**
    - By continued productivity improvement despite rising raw material prices, GPM may increase from 70.4% to 70.9% (GPM excluding forex rate 71.2%)
  - **SGA expenses 62,609 Mil. Yen (YoY+9.4%)**
    - Increase in expenses for strengthening sales& marketing activities
    - Increase in R&D expenses (15,239 Mil. Yen, sales ratio 9.4%)
    - Increase expenses associated with preparations for the start-up of the Nanning factory in China (production to begin in 2030)
    - Increase in personnel expenses, etc. to strengthen the management foundation
  - **Ordinary income 52,600 Mil. Yen(YoY +16.4%)**
  - **Net income attributable to parent company shareholders:37,832 Mil. Yen (YoY +17.9%)**

Exchange rate (Unit : JPY)	US＄	EURO	CNY	BAHT
FYE June 2027 Plan	155.00	179.00	22.00	4.90
FYE June 2026 Results	154.45	180.11	22.10	4.80

Effect of exchange rate on operating profit (Main currency)

US＄ (+ 1 yen influence) : approx.	203 Mil. Yen Increase
EURO (+ 1 yen influence) : approx.	130 Mil. Yen Increase
CNY (+ 1 yen influence) : approx.	1,824 Mil. Yen Increase
BAHT(+0.1 yen influence) : approx.	348 Mil. Yen Decrease

Earnings Forecast for FYE June 2027

	FYE June 2026 Results		FYE June 2027 Plan			
					YoY	
	Amount (Mil.Yen)	Ratio (%)	Amount (Mil.Yen)	Ratio(%)	Changes (Mil.Yen)	Changes (%)
Revenue	145,419	100.0	161,794	100.0	+16,374	+11.3
Gross profit	102,447	70.4	114,737	70.9	+12,289	+12.0
Operating profit	45,218	31.1	52,127	32.2	+6,908	+15.3
Ordinary income	45,185	31.1	52,600	32.5	+7,414	+16.4
Net income attributable to parent company shareholders	32,075	22.1	37,832	23.4	+5,756	+17.9
EPS (Yen)	120.59	–	142.59	–	+22.00	+18.2

(Reference) At the same exchange rate as the previous year			
		YoY	
Amount (Mil.Yen)	Ratio (%)	Changes (Mil.Yen)	Changes (%)
161,969	100.0	+16,550	+11.4
115,280	71.2	+12,833	+12.5
52,753	32.6	+7,534	+16.7

Exchange rate (Unit : JPY)	US＄	EURO	CNY	BAHT
FYE June 2027 Plan	155.00	179.00	22.00	4.90
FYE June 2026 Results	154.45	180.11	22.10	4.80

Earnings Forecast by Segment





Attribution Analysis of Operating profit – 1
(Exchange Rate Fluctuations Included)



Exchange rate (Unit：JPY)	US＄	EURO	CNY	BAHT
FYE June 2027 Plan	155.00	179.00	22.00	4.90
FYE June 2026 Results	154.45	180.11	22.10	4.80

Attribution Analysis of Operating profit – 2
(Exchange Rate Fluctuations Excluded)



Exchange rate (Unit : JPY)	US＄	EURO	CNY	BAHT
FYE June 2027 Plan	**155.00**	**179.00**	**22.00**	**4.90**
FYE June 2026 Results	**154.45**	**180.11**	**22.10**	**4.80**

Your dreams. Woven together.
ASAHI INTECC

R&D Expenses

Continuing aggressive investment <Criteria : R&D to sales ratio upper limit 12%, Mid-term plan: 11%>
Since a high proportion of sales is denominated in foreign currencies, while the majority of R&D expenses are denominated in yen, this ratio tends to be lower when the yen weakens.
The transfer of operations to the Thai plant is being implemented in phases and is progressing smoothly.



Capital Expenditure : Results and Plan

Investment in Chinese factory is expected to largely wrap up in the next discal year, and regular investment is also showing signs of being curtailed



Main investment matter (Mil. Yen)	FYE June 2023	FYE June 2024	FYE June 2025	FYE June 2026	FYE June 2027 Plan
HQ Expansion of New Building R&D base	**3,559**	**4,224**			
Expansion of Shizuoka R&D Center		**776**	**1,099**		
Expansion of Thailand factory	**1,213**	**717**			
Expansion of Hanoi factory	**1,396**	**1,114**	**1,448**		
Expansion of Cebu factory	**749**		**691**		
Launch of factory in China				**911**	**1,066**
Shinagawa Office: Catheter Lab Installation					**700**

※Only projects more than 500 Mil. Yen are listed.

Caution Regarding Information Presented

All forward looking statements contained herein, including revenue forecasts, outlooks, and strategic plans, are based on the best currently available data; however, risk and uncertainty are involved in these statements.
Please note that actual results may differ greatly from plans presented here.

【 IR contact 】

Asahi Intecc Co., Ltd.
corporate strategic office

TEL 0561-56-1851
URL https://www.asahi-intecc.co.jp/en